300109.SHE Boai NKY Pharmaceuticals Ltd
- Market cap
- CNY 6.20B
- P/E
- 51.2x
- P/B
- 1.81x
- ROE
- 5.3%
- Dividend yield
- 2.09%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300109.SHE undervalued?
Graham number300109.SHE trades 103.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Boai NKY Pharmaceuticals Ltd fundamental analysis
No fundamental analysis for Boai NKY Pharmaceuticals Ltd yet.
Boai NKY Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP) series products, vinyl methyl ether/maleic anhydride copolymer (PVM/MA, Euroster) copolymer, and oral care products; and medical technology services, such as early tumor screening, molecular diagnostics, and precision medicine. It also offers pharmaceutical; hazardous chemical; food additive; me…
Full company profileBoai NKY Pharmaceuticals Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Boai NKY Pharmaceuticals Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 401M | 489M | 698M | 924M | 979M | 1.22B | 1.49B | 1.58B | 1.61B | 1.18B | 1.31B |
| Gross Profit | 175M | 232M | 316M | 442M | 430M | 487M | 691M | 894M | 750M | 539M | 520M |
| Operating Income | 92.5M | 107M | 107M | 156M | 64.6M | 285M | 389M | 585M | 408M | 297M | 251M |
| EBITDA | 133M | 148M | 179M | 252M | 172M | 401M | 455M | 663M | 504M | 354M | 227M |
| Net Income | 80.0M | 92.8M | 89.5M | 123M | 44.6M | 207M | 291M | 493M | 350M | 190M | 180M |
| EPS | 0.24 | 0.28 | 0.27 | 0.30 | 0.09 | 0.41 | 0.57 | 1.02 | 0.72 | 0.33 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 1.31B | 1.96B | 2.30B | 4.20B | 4.15B | 3.99B | 3.71B | 4.02B | 4.37B | 4.37B | 4.36B |
| Total Liabilities | 83.3M | 656M | 1.03B | 1.14B | 1.07B | 590M | 596M | 500M | 764M | 713M | 1.01B |
| Shareholders' Equity | 1.23B | 1.30B | 1.27B | 3.05B | 3.08B | 3.41B | 3.14B | 3.55B | 3.64B | 3.68B | 3.38B |
| Cash & Short-term Investments | 199M | 379M | 253M | 285M | 277M | 1.36B | 577M | 325M | 578M | 692M | 516M |
| Total Debt | 9.90M | 545M | 688M | 938M | 767M | 99.0M | 72.6M | 47.6M | 294M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 114M | 47.3M | 48.8M | 79.6M | 267M | 43.4M | 252M | 488M | 256M | 338M | - |
| Capital Expenditure | 48.5M | 129M | 124M | 142M | 99.2M | 228M | 266M | 378M | 275M | 220M | 194M |
| Free Cash Flow | 65.7M | -82.0M | -75.6M | -62.7M | 168M | -185M | -14.2M | 110M | -18.7M | 118M | 71.3M |
| Ratios | |||||||||||
| ROE | 6.5% | 7.1% | 7.0% | 4.0% | 1.4% | 6.1% | 9.3% | 13.9% | 9.6% | 5.2% | 5.3% |
| ROA | 6.1% | 4.7% | 3.9% | 2.9% | 1.1% | 5.2% | 7.8% | 12.3% | 8.0% | 4.4% | 4.1% |
| Net Profit Margin | 20.0% | 19.0% | 12.8% | 13.3% | 4.6% | 17.0% | 19.6% | 31.1% | 21.8% | 16.1% | 13.7% |
| Debt to Equity | 0.01x | 0.42x | 0.54x | 0.31x | 0.25x | 0.03x | 0.02x | 0.01x | 0.08x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Boai NKY Pharmaceuticals Ltd dividends
- Dividend yield
- 2.09%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 68.0%
- Ex-dividend date
- Jun 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 129M | 0.22 | 68.0% |
| 2024 | CNY 329M | 0.68 | 94.0% |
| 2023 | CNY 162M | 0.34 | 32.8% |
| 2022 | CNY 168M | 0.33 | 57.6% |
| 2021 | CNY 6.46M | 0.01 | 3.1% |
| 2020 | CNY 6.46M | 0.01 | 14.5% |
| 2019 | CNY 21.8M | 0.05 | 17.7% |
| 2018 | CNY 42.2M | 0.13 | 47.1% |
| 2017 | CNY 20.6M | 0.06 | 22.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 23, 2026.
Who owns Boai NKY Pharmaceuticals Ltd
- Insiders 25.63%
- Institutions 2.47%
- Public & others 71.90%
- Shares outstanding 577M
- Free float 452M
Boai NKY Pharmaceuticals Ltd company profile
- Company name
- Boai NKY Pharmaceuticals Ltd
- Ticker
- 300109.SHE
- ISIN
- CNE100000SV3
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 25, 2010
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 1,186
- Fiscal year end
- December
- Address
- No. 1888, Wenhua Road, Jiaozuo, China, 454450
- Phone
- 86 39 1861 0680
- Website
- boai-nky.com
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP) series products, vinyl methyl ether/maleic anhydride copolymer (PVM/MA, Euroster) copolymer, and oral care products; and medical technology services, such as early tumor screening, molecular diagnostics, and precision medicine. It also offers pharmaceutical; hazardous chemical; food additive; medical protective equipment; medical device; manufacturing of basic chemical raw materials; import and export of goods and technology; technical services; and technology development, consulting, exchange, transfer, and promotion. The company was formerly known as Boai NKY Pharmaceuticals Ltd. and changed its name to Boai NKY Medical Holdings Ltd. in March 2016. Boai NKY Medical Holdings Ltd. was founded in 1987 and is based in Jiaozuo, China.
Boai NKY Pharmaceuticals Ltd management
10- Mr. Junzheng ZhangChairman of the Board & GM · born 1976
- Mr. Ai Min LiuCFO & Financial Director · born 1973
- Ms. Yunxia QuSenior VP & Director · born 1970
- Mr. Jiangtao YuSenior VP & Director · born 1982
- Mr. Xiaoliang XingDeputy GM & Board Secretary · born 1971
- Mr. Dedong ZhangDeputy General Manager · born 1972
- Mr. Shigang WangDeputy General Manager · born 1989
- Mr. Xiaowen ZouDeputy General Manager · born 1977
- Mr. Haizhan MaoDeputy General Manager · born 1974
- Mr. Shegang LiDeputy General Manager · born 1964